Robust medical: it plans to acquire the controlling equity of Hunan Ping An medical equipment
According to the prudent medical announcement, the company plans to purchase 65.5528% of the equity of Hunan Ping An medical equipment Technology Co., Ltd. from the shareholders of Hunan Ping An medical equipment Technology Co., Ltd. with RMB 652 million, and use RMB 100 million to unilaterally increase the capital of Hunan Ping An medical equipment. After the completion of the above transaction, the company will invest RMB 752 million and hold 68.7% of the equity after the capital increase and share expansion of Hunan Ping An medical equipment. The main business of Hunan Ping An medical equipment is the R & D, production and sales of medical devices such as syringes, infusion sets, blood collection vessels, blood collection needles and indwelling needles.
This text is a result of machine translation.
Related companies：
In-depth
Briefing Yesterday 04:29 PM
· Healthcare
Shuidi company has established a new pharmaceutical innovation division to further develop the pharmaceutical direction
Apr 18, 2022 06:30 PM
Apr 22, 2021 03:11 PM
Research
Healthcare, Technology, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Briefing Jan 14, 2022 01:18 PM
· Healthcare
Mask protection unit rose in the afternoon
Healthcare
Biotech Firm ImmuneOnco Submitted Listing Application on the Main Board of HKEX
ImmuneOnco, focusing on developing new-generation tumor immunotherapeutic, will further accelerate the development of other promising drug candidates targeting checkpoints of innate and adaptive immunity.
Yesterday 10:58 PM
Briefing Jan 05, 2022 09:49 PM
· Healthcare
Imber: the shareholder Ruan bin has completed the reduction of 337500 shares and plans to continue to reduce no more than 1.32% of the shares
Briefing Nov 01, 2021 07:34 PM
· Healthcare
Robust medical: by the end of October, 1159400 shares had been repurchased
In-depth
Healthcare
BeiGene: a Vast Opportunity Lies Ahead – But We Remain Cautious
BeiGene, a leader in China's novel pharmaceutical industry, recently received approval in Kuwait, Bahrain, and Qatar for its medication BRUKINSA (zanubrutinib). Previous contracts with major biopharma have produced substantial licensing income, but they did not lessen BeiGene's financial burden.
Jun 24, 2022 12:13 PM
Briefing Aug 03, 2021 02:55 PM
· Healthcare
Robust medical treatment: affected by the recent spread of delta virus strain, the company's demand for protective products such as masks and protective clothing has increased significantly
Briefing Jul 22, 2021 07:33 PM
· Healthcare
Xinxiang Chemical Fiber: some production workshops of viscose filament are temporarily shut down due to water inflow
See more
Read next
In-depth
Technology
A Closer Look at China’s Cloud Service Market, Guessing Who Will Succeed? [1/2]
Jun 27, 2022 05:09 PM
In-depth
Healthcare
Exclusive Interview with Xu Qian, Managing Partner of Redhill Capital
Jun 27, 2022 12:24 PM
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.